Dan Ziegler1,2,3, Alexander Strom4,5, Klaus Straßburger5,6, Birgit Knebel5,7, Gidon J Bönhof4,8, Jörg Kotzka5,7, Julia Szendroedi4,8,5, Michael Roden4,8,5. 1. Institute for Clinical Diabetology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. dan.ziegler@ddz.de. 2. Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. dan.ziegler@ddz.de. 3. German Center for Diabetes Research (DZD), München-Neuherberg, Germany. dan.ziegler@ddz.de. 4. Institute for Clinical Diabetology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. 5. German Center for Diabetes Research (DZD), München-Neuherberg, Germany. 6. Institute for Biometrics and Epidemiology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. 7. Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. 8. Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Abstract
AIMS/HYPOTHESIS: Emerging evidence suggests that in addition to hyperglycaemia, dyslipidaemia could represent a contributing pathogenetic factor to diabetic neuropathy, while obesity and insulin resistance play a role in the development of diabetic cardiac autonomic neuropathy (CAN) characterised by reduced heart rate variability (HRV), particularly in type 2 diabetes. We hypothesised that distinct lipid metabolites are associated with diminished HRV in recent-onset type 2 diabetes rather than type 1 diabetes. METHODS: We analysed 127 plasma lipid metabolites (11 acylcarnitines, 39 NEFA, 12 sphingomyelins (SMs), 56 phosphatidylcholines and nine lysophosphatidylcholines) using MS in participants from the German Diabetes Study baseline cohort recently diagnosed with type 1 (n = 100) and type 2 diabetes (n = 206). Four time-domain HRV indices (number of normal-to-normal (NN) intervals >50 ms divided by the number of all NN intervals [pNN50]; root mean square of successive differences [RMSSD]; SD of NN intervals [SDNN]; and SD of differences between adjacent NN intervals) and three frequency-domain HRV indices (very-low-frequency [VLF], low-frequency [LF] and high-frequency [HF] power spectrum) were computed from NN intervals recorded during a 3 h hyperinsulinaemic-euglycaemic clamp at baseline and in subsets of participants with type 1 (n = 60) and type 2 diabetes (n = 95) after 5 years. RESULTS: In participants with type 2 diabetes, after Bonferroni correction and rigorous adjustment, SDNN was inversely associated with higher levels of diacyl-phosphatidylcholine (PCaa) C32:0, PCaa C34:1, acyl-alkyl-phosphatidylcholine (PCae) C36:0, SM C16:0 and SM C16:1. SD of differences between NN intervals was inversely associated with PCaa C32:0, PCaa C34:1, PCaa C34:2, PCae C36:0 and SM C16:1, and RMSSD with PCae C36:0. For VLF power, inverse associations were found with PCaa C30:0, PCaa C32:0, PCaa C32:1, PCaa C34:2 and SM C16:1, and for LF power inverse associations were found with PCaa C32:0 and SM C16:1 (r = -0.242 to r = -0.349; p ≤ 0.0005 for all correlations). In contrast, no associations of lipid metabolites with measures of cardiac autonomic function were noted in participants recently diagnosed with type 1 diabetes. After 5 years, HRV declined due to ageing rather than diabetes, whereby prediction analyses for lipid metabolites were hampered. CONCLUSIONS/ INTERPRETATION: Higher plasma levels of specific lipid metabolites are closely linked to cardiac autonomic dysfunction in recent-onset type 2 diabetes but not type 1 diabetes, suggesting a role for perturbed lipid metabolism in the early development of CAN in type 2 diabetes. Graphical abstract.
AIMS/HYPOTHESIS: Emerging evidence suggests that in addition to hyperglycaemia, dyslipidaemia could represent a contributing pathogenetic factor to diabetic neuropathy, while obesity and insulin resistance play a role in the development of diabetic cardiac autonomic neuropathy (CAN) characterised by reduced heart rate variability (HRV), particularly in type 2 diabetes. We hypothesised that distinct lipid metabolites are associated with diminished HRV in recent-onset type 2 diabetes rather than type 1 diabetes. METHODS: We analysed 127 plasma lipid metabolites (11 acylcarnitines, 39 NEFA, 12 sphingomyelins (SMs), 56 phosphatidylcholines and nine lysophosphatidylcholines) using MS in participants from the German Diabetes Study baseline cohort recently diagnosed with type 1 (n = 100) and type 2 diabetes (n = 206). Four time-domain HRV indices (number of normal-to-normal (NN) intervals >50 ms divided by the number of all NN intervals [pNN50]; root mean square of successive differences [RMSSD]; SD of NN intervals [SDNN]; and SD of differences between adjacent NN intervals) and three frequency-domain HRV indices (very-low-frequency [VLF], low-frequency [LF] and high-frequency [HF] power spectrum) were computed from NN intervals recorded during a 3 h hyperinsulinaemic-euglycaemic clamp at baseline and in subsets of participants with type 1 (n = 60) and type 2 diabetes (n = 95) after 5 years. RESULTS: In participants with type 2 diabetes, after Bonferroni correction and rigorous adjustment, SDNN was inversely associated with higher levels of diacyl-phosphatidylcholine (PCaa) C32:0, PCaa C34:1, acyl-alkyl-phosphatidylcholine (PCae) C36:0, SM C16:0 and SM C16:1. SD of differences between NN intervals was inversely associated with PCaa C32:0, PCaa C34:1, PCaa C34:2, PCae C36:0 and SM C16:1, and RMSSD with PCae C36:0. For VLF power, inverse associations were found with PCaa C30:0, PCaa C32:0, PCaa C32:1, PCaa C34:2 and SM C16:1, and for LF power inverse associations were found with PCaa C32:0 and SM C16:1 (r = -0.242 to r = -0.349; p ≤ 0.0005 for all correlations). In contrast, no associations of lipid metabolites with measures of cardiac autonomic function were noted in participants recently diagnosed with type 1 diabetes. After 5 years, HRV declined due to ageing rather than diabetes, whereby prediction analyses for lipid metabolites were hampered. CONCLUSIONS/ INTERPRETATION: Higher plasma levels of specific lipid metabolites are closely linked to cardiac autonomic dysfunction in recent-onset type 2 diabetes but not type 1 diabetes, suggesting a role for perturbed lipid metabolism in the early development of CAN in type 2 diabetes. Graphical abstract.
Authors: Timothy R Koves; John R Ussher; Robert C Noland; Dorothy Slentz; Merrie Mosedale; Olga Ilkayeva; James Bain; Robert Stevens; Jason R B Dyck; Christopher B Newgard; Gary D Lopaschuk; Deborah M Muoio Journal: Cell Metab Date: 2008-01 Impact factor: 27.287
Authors: Kelli M Sas; Jiahe Lin; Thekkelnaycke M Rajendiran; Tanu Soni; Viji Nair; Lucy M Hinder; Hosagrahar V Jagadish; Thomas W Gardner; Steven F Abcouwer; Frank C Brosius; Eva L Feldman; Matthias Kretzler; George Michailidis; Subramaniam Pennathur Journal: J Lipid Res Date: 2017-12-13 Impact factor: 5.922
Authors: A Othman; M F Rütti; D Ernst; C H Saely; P Rein; H Drexel; C Porretta-Serapiglia; G Lauria; R Bianchi; A von Eckardstein; T Hornemann Journal: Diabetologia Date: 2011-11-29 Impact factor: 10.122
Authors: William L Holland; Joseph T Brozinick; Li-Ping Wang; Eric D Hawkins; Katherine M Sargent; Yanqi Liu; Krishna Narra; Kyle L Hoehn; Trina A Knotts; Angela Siesky; Don H Nelson; Sotirios K Karathanasis; Greg K Fontenot; Morris J Birnbaum; Scott A Summers Journal: Cell Metab Date: 2007-03 Impact factor: 27.287
Authors: Peter J Meikle; Gerard Wong; Ricardo Tan; Philippe Giral; Paul Robillard; Alexina Orsoni; Neil Hounslow; Dianna J Magliano; Jonathan E Shaw; Joanne E Curran; John Blangero; Bronwyn A Kingwell; M John Chapman Journal: J Lipid Res Date: 2015-10-20 Impact factor: 5.922
Authors: Yanping Li; Dong D Wang; Stephanie E Chiuve; JoAnn E Manson; Walter C Willett; Frank B Hu; Lu Qi Journal: Diabetes Care Date: 2015-02 Impact factor: 19.112
Authors: Christian S Hansen; Tommi Suvitaival; Simone Theilade; Ismo Mattila; Maria Lajer; Kajetan Trošt; Linda Ahonen; Tine W Hansen; Cristina Legido-Quigley; Peter Rossing; Tarunveer S Ahluwalia Journal: Front Endocrinol (Lausanne) Date: 2022-04-14 Impact factor: 6.055
Authors: Farsad Afshinnia; Evan L Reynolds; Thekkelnaycke M Rajendiran; Tanu Soni; Jaeman Byun; Masha G Savelieff; Helen C Looker; Robert G Nelson; George Michailidis; Brian C Callaghan; Subramaniam Pennathur; Eva L Feldman Journal: Ann Clin Transl Neurol Date: 2022-08-03 Impact factor: 5.430